Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease; Pharmaceutical preparations for the prevention and treatment of depression; Pharmaceutical preparations for the prevention and treatment of psychological disorders; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of cardiovascular and blood pressure disorders; Pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of osteoporosis; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of sexual dysfunction; Pharmaceutical preparations for the prevention and treatment of symptoms associated with uterine fibroids; Pharmaceutical preparations for the prevention and treatment of urinary incontinence and overactive bladder; Pharmaceutical preparations for the prevention and treatment of AIDS-related disorders; Pharmaceutical preparations that support, encourage and promote bone strength; Pharmaceutical preparations that support, encourage and promote bone health; Pharmaceutical preparations used in the treatment of bone disorders and bone diseases; Pharmaceutical preparations, namely, injectable contraceptives; Pharmaceutical preparations, namely, contraceptive preparations; Pharmaceutical preparations, namely, fertility enhancement preparations; Pharmaceutical preparations, namely, hormone replacement therapy preparations; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical agents affecting the central nervous system; Pharmaceutical agents affecting circulatory systems; Pharmaceutical agents affecting sensory organs; Pharmaceutical agents affecting urogenital organs; Pharmaceutical agents affecting peripheral nervous system

First Use Date in General

21^st Sep 2020

First Use Date in Commerce

21^st Sep 2020

Mark Details

Serial Number

No 87352575

Mark Type

No Service/Collective Mark

Attorney Docket Number

44D Filed

44D Current

44E filed

44E Current

66A Filed

66A Current

Current Basis

No Basis

Design Code(s)

05.03.08 -

More than one leaf, including scattered leaves, bunches of leaves not attached to branches

26.17.06 -

Diagonal line(s), band(s) or bar(s)

26.17.09 -

Curved line(s), band(s) or bar(s)

27.03.04 -

Representations of plants or parts of plants forming letters or numerals, including punctuation

Legal History

Status Date	Action Taken
15^th Dec 2020	REGISTERED-PRINCIPAL REGISTER
10^th Nov 2020	NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
09^th Nov 2020	ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
05^th Nov 2020	NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
05^th Nov 2020	SU-EXAMINER'S AMENDMENT WRITTEN
05^th Nov 2020	EXAMINER'S AMENDMENT ENTERED
05^th Nov 2020	EXAMINERS AMENDMENT E-MAILED
30^th Oct 2020	STATEMENT OF USE PROCESSING COMPLETE
20^th Oct 2020	USE AMENDMENT FILED
20^th Oct 2020	TEAS STATEMENT OF USE RECEIVED

TEVA

Classification Information

Class [005]Pharmaceutical Products